Amarin Corporation plc (AMRN) Income Statement

NASDAQ: AMRNRevenue, profits, margins and EPS over 10 years.

AMRN 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Revenue−6.5%
$213.6M
2025 · hover or tap a bar for each year
2016: $130.1M (+59.1%)2017: $181.1M (+39.2%)2018: $229.2M (+26.6%)2019: $429.8M (+87.5%)2020: $614.1M (+42.9%)2021: $583.2M (−5.0%)2022: $369.2M (−36.7%)2023: $306.9M (−16.9%)2024: $228.6M (−25.5%)2025: $213.6M (−6.5%)
20162025
Gross profit+48.5%
$120.9M
2025 · hover or tap a bar for each year
2016: $95.7M (+77.7%)2017: $136.2M (+42.2%)2018: $174.7M (+28.3%)2019: $333.7M (+91.1%)2020: $482.6M (+44.6%)2021: $461.9M (−4.3%)2022: $242.5M (−47.5%)2023: $165.5M (−31.7%)2024: $81.4M (−50.8%)2025: $120.9M (+48.5%)
20162025
Operating income
−$13.9M
2025 · hover or tap a bar for each year
2016: −$65.6M2017: −$45.6M2018: −$108.2M2019: −$24.3M2020: −$19.7M2021: $10.5M2022: −$105.9M (−1,108.1%)2023: −$56.6M2024: −$91.8M2025: −$13.9M
20162025
Net income
−$38.8M
2025 · hover or tap a bar for each year
2016: −$86.3M2017: −$67.9M2018: −$116.4M2019: −$22.6M2020: −$18.0M2021: $7.7M2022: −$105.8M (−1,468.9%)2023: −$59.1M2024: −$82.2M2025: −$38.8M
20162025
EPS (diluted)
$0.27
2025 · hover or tap a bar for each year
2016: −$6.532017: −$3.482018: −$5.712019: −$1.782020: −$1.392021: $1.162022: −$2.24 (−293.1%)2023: $0.742024: −$1.12 (−251.4%)2025: $0.27
20162025
Net profit margin+17.8 pts
−18.2%
2025 · hover or tap a point for each year
2016: −66.4% (+74.5 pts)2017: −37.5% (+28.9 pts)2018: −50.8% (−13.3 pts)2019: −5.3% (+45.5 pts)2020: −2.9% (+2.3 pts)2021: 1.3% (+4.3 pts)2022: −28.7% (−30.0 pts)2023: −19.3% (+9.4 pts)2024: −35.9% (−16.7 pts)2025: −18.2% (+17.8 pts)
20162025

AMRN revenue and net income

RevenueNet incomeNet margin (right axis)

Where AMRN's revenue goes

2025
Revenue
$213.6M100.0%
Cost of revenue
−$92.8M−43.4%
Gross profit
$120.9M56.6%
Research & development
−$19.8M−9.3%
Sales, general & admin
−$115.0M−53.8%
Operating income
−$13.9M−6.5%
Interest & other expense
−$22.1M−10.3%
Income taxes
−$2.8M−1.3%
Net income
−$38.8M−18.2%

Each bar shows an amount and its share of revenue. AMRN kept −18.2% of revenue as net income.

AMRN profit margins

GrossOperatingNet

AMRN growth rates

to 2025
1 year3 years5 years10 years
Revenue−6.5%−16.7%−19.0%+10.1%
Gross profit+48.5%−20.7%−24.2%+8.4%
Operating income————
Net income————
EPS (diluted)————

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

AMRN quarterly EPS vs estimates

Reported EPSAnalyst estimate

Amarin beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.28).

AMRN income statement

Amarin Corporation plc annual income statement
2025202420232022202120202019201820172016
Revenue$213.6M$228.6M$306.9M$369.2M$583.2M$614.1M$429.8M$229.2M$181.1M$130.1M
Cost of revenue$92.8M$147.2M$141.4M$126.7M$121.3M$131.4M$96.0M$54.5M$45.0M$34.4M
Gross profit$120.9M$81.4M$165.5M$242.5M$461.9M$482.6M$333.7M$174.7M$136.2M$95.7M
Research & development$19.8M$20.9M$22.2M$30.4M$29.3M$39.0M$34.4M$55.9M$47.2M$50.0M
Sales, general & admin$115.0M$152.3M$199.9M$304.4M$408.3M$463.3M$323.6M$227.0M$134.5M$111.4M
Total operating expenses$134.8M$173.2M$222.2M$348.4M$451.4M$502.3M$358.0M$282.9M$181.7M$161.3M
Operating income−$13.9M−$91.8M−$56.6M−$105.9M$10.5M−$19.7M−$24.3M−$108.2M−$45.6M−$65.6M
Interest income$10.9M$13.4M$10.0M$2.8M$1.2M$4.9M$8.5M$1.1M$429,000$234,000
Interest expense$7,000$7,000$8,000$15,000$129,000$2.6M$6.6M$8.9M$9.8M$18.7M
Income before taxes−$36.0M−$77.2M−$53.7M−$103.8M$11.3M−$17.3M−$22.5M−$116.3M−$55.4M−$76.4M
Income taxes$2.8M$5.0M$5.4M$2.0M$3.6M$745,000$164,000$96,000$13.0M$10.0M
Net income−$38.8M−$82.2M−$59.1M−$105.8M$7.7M−$18.0M−$22.6M−$116.4M−$67.9M−$86.3M
EBITDA−$33.0M−$74.3M−$50.7M−$100.7M$14.3M−$12.7M−$15.0M−$106.6M−$44.3M−$56.5M
EPS (diluted)$0.27−$1.12$0.74−$2.24$1.16−$1.39−$1.78−$5.71−$3.48−$6.53
Gross margin56.6%35.6%53.9%65.7%79.2%78.6%77.7%76.2%75.2%73.6%
Operating margin−6.5%−40.2%−18.4%−28.7%1.8%−3.2%−5.6%−47.2%−25.2%−50.4%
Net margin−18.2%−35.9%−19.3%−28.7%1.3%−2.9%−5.3%−50.8%−37.5%−66.4%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AMRN's financial statements (latest annual report filed March 2, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

AMRN financial results

In fiscal year 2025 (ended December 31, 2025), Amarin reported revenue of $213.6 million, down 6.5% from the year before. It had a net loss of $38.8 million, a net profit margin of −18.2%. Diluted earnings per share came to $0.27. Over five years revenue grew at an average rate of −19.0% a year.

See the AMRN stock overview for the latest quote and news, or the AMRN chart for price history and technical indicators.

AMRN income statement FAQ

What is Amarin's annual revenue?

Amarin reported total revenue of $213.6 million for fiscal year 2025, which ended on December 31, 2025. That was down 6.5% from $228.6 million the previous year.

Is Amarin profitable?

No. Amarin reported a net loss of $38.8 million in fiscal 2025, a net profit margin of −18.2%; its operating margin was −6.5%.

What is Amarin's gross margin?

Amarin's gross margin was 56.6% in fiscal 2025: for every $100 of revenue, Amarin kept $57 after the direct cost of its products and services.

How much does Amarin spend on research and development?

Amarin spent $19.8 million on research and development in fiscal 2025, 9.3% of revenue.

How fast is Amarin growing?

Revenue grew −19.0% a year on average over the last five fiscal years, from $614.1 million to $213.6 million.

What are Amarin's earnings per share?

Amarin earned $0.27 per diluted share in fiscal 2025, compared with $-1.12 a year earlier.

When will Amarin report its next earnings?

Amarin is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.

When does Amarin's fiscal year end?

Amarin's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 2, 2026.

Drug Manufacturers - General income statements